StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

7-Epi-Taxol

HCID 184492
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
105454-04-4
Standard-SMILES
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
InChIKey
RCINICONZNJXQF-LYTKHFMESA-N
Summenformel
C47H51NO14
Durchschnittliche Molmasse
853,9 g/mol
Monoisotopische Masse
853,3309553

Überblick

7-epitaxol has been reported in Taxus cuspidata, Corylus avellana, and other organisms with data available.

Namen und Bezeichner

Bevorzugter Name
7-Epi-Taxol
IUPAC
[(1S,2S,3R,4S,7R,9R,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Englischer Name
7-Epitaxol
Summenformel
C47H51NO14
Molmasse
853.91

Namen und Synonyme

7-Epitaxol7-epi-Taxol105454-04-4EpitaxolVRA3UAZ8BLDTXSID201318105[(1S,2S,3R,4S,7R,9R,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate((1S,2S,3R,4S,7R,9R,10S,12R,15S)-4,12-diacetyloxy-15-((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo(11.3.1.03,10.04,7)heptadec-13-en-2-yl) benzoateRefChem:546330DTXCID7017478947-Epipaclitaxel7-epi-Paclitaxel
Weitere Namen anzeigen
EPITAXOL, 7-7-Epitaxol ,S9265Paclitaxel Impurity E7-Epipaclitaxel(crude)PROTAC MPS1 degrader 2Paclitaxel 7-Epi-Impurity7-Epitaxol 7-Epipaclitaxel7-epi-Taxol, 10 mM in DMSO
Paclitaxel EP Impurity EMFCD077837137-Epi Paclitaxel(2aR,4R,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-Benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetateC47H51NO147-Epipaclitaxel?CHEMBL503883orb1303347

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,5
Polarare Oberfläche (TPSA)
221 Ų
H-Brücken-Donoren
4
H-Brücken-Akzeptoren
14
Frei drehbare Bindungen
14
Schwere Atome
62
Formalladung
0
Komplexität
1.790

Physikochemische Eigenschaften

Schmelzpunkt
168 · 168-170C
Siedepunkt
957.1 · 957.1±65.0 °C(Predicted)
Dichte
1.39 · 1.39±0.1 g/cm3 (20 ºC 760 Torr)
storage temp.
2 · Inert atmosphere,2-8°C
Löslichkeit
25 mg/ml; · DMF: 25 mg/ml; DMF:PBS (pH 7.2)(1:3): 0.25 mg/ml; DMSO: 10 mg/ml; Ethanol: 5 mg/ml
Aggregatzustand
A crystalline solid
pka
11.9 · 11.90±0.20(Predicted)
Farbe
White to off-white
InChIKey
RCINICONZNJXQF-WLUSQHPBSA-N

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P316, P302+P352, P304+P340, P305+P354+P338, P317, P318, P319, P321, P330, P332+P317, P333+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 3 (33.3%)

Toxikologische Informationen

Exposure RoutesWhen a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the maximum plasma concentration (Cmax) is 195 ng/mL, while the AUC is 6300 ng*h/mL.
Toxicity Summary · 1 Eintrag

Paclitaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, paclitaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, paclitaxel binds to the β subunit of tubulin. Tubulin is the 'building block' of mictotubules, and the binding of paclitaxel locks these building blocks in place. The resulting microtubule/paclitaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that paclitaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

Chemie und Industrie

Pharmakologische Informationen

Metabolism/Metabolites · 1 Eintrag

Hepatic. In vitro studies with human liver microsomes and tissue slices showed that paclitaxel was metabolized primarily to 6a-hydrox-ypaclitaxel by the cytochrome P450 isozyme CYP2C8; and to two minor metabolites, 3’-p-hydroxypaclitaxel and 6a, 3’-p-dihydroxypaclitaxel, by CYP3A4. Route of Elimination: In 5 patients administered a 225 or 250 mg/m2 dose of radiolabeled paclitaxel as a 3-hour infusion, a mean of 71% of the radioactivity was excreted in the feces in 120 hours, and 14% was recovered in the urine. Half Life: When a 24 hour infusion of 135 mg/m^2 is given to ovarian cancer patients, the elimination half=life is 52.7 hours.

MeSH Pharmacological Classification · 2 Einträge

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

Verwendung und Herstellung

UsesUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane™ is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Anwendungen

Verwenden7-Epitaxol has been isolated from Taxus brevifolia. It is an antineoplastic that is currently being used in cancer research. Paclitaxel EP Impurity E.

Zugehörige Reaktionen

10
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 590947
HRID 590947als Edukt
Reaktionsgleichung von HRID 590948
HRID 590948als Edukt
Reaktionsgleichung von HRID 657446
HRID 657446als Edukt
Reaktionsgleichung von HRID 657447
HRID 657447als Edukt
Reaktionsgleichung von HRID 1182625
HRID 1182625als Edukt
Reaktionsgleichung von HRID 1182626
HRID 1182626als Edukt
Reaktionsgleichung von HRID 1712858
HRID 1712858als Edukt
Reaktionsgleichung von HRID 1712859
HRID 1712859als Edukt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
105454-04-4
PubChem CID
184492
DTXSID
DTXSID201318105
ChEMBL
CHEMBL503883
UNII
VRA3UAZ8BL
EC Number
630-563-3
Nikkaji
J624.351G
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Toxicity DataRat (ipr) LD<sub>50</sub>=32530 &micro;g/kg.

Sicherheitsdaten

hs_code
2932999026